KRAS G12C结直肠癌新进展：索托拉西布联合帕尼单抗最新生存数据 (CodeBreaK 300研究) – medfind.link

Sotorazib is a prescription drug that targets the KRAS G12C mutant protein. It received accelerated approval from the U.S. FDA on May 28, 2021. Patients should use it only as directed by their doctor.

Regorafenib is a multi-target tyrosine kinase inhibitor primarily used to treat metastatic colorectal cancer (mCRC).

Cannefenib is a prescription drug approved by the U.S. Food and Drug Administration (FDA) in 2018. It is used for BRAF V600E and BRAF V600K gene mutations that require FDA approval for testing confirmation. It should be used strictly in accordance with your doctor's instructions.

Larotrectinib is a potent, oral, selective tropomyosin receptor kinase (TRK) inhibitor designed to directly target TRKs (including TRKB, TRKC, and TRK2), shutting down the signaling pathways that lead to the growth of TRK fusion-related tumors. Larotrectinib is a "cancer-agnostic" therapy; it is the world's first oral TRK inhibitor specifically designed for patients with NTRK gene fusion-related cancers. NTRK gene fusions are found in various solid tumor types, including pancreatic cancer, thyroid cancer, salivary gland cancer, breast cancer, colorectal cancer, and lung cancer, especially in some rare cancers such as infantile fibrosarcoma, secretory carcinoma-like breast cancer, and secretory breast cancer...

Dabrafenib is a BRAF inhibitor cancer drug, available as a mesylate. On May 29, 2013, the U.S. Food and Drug Administration (FDA) simultaneously approved the marketing applications of dabrafenib and trametinib. Dabrafenib is approved for the treatment of unresectable melanoma (tumors that cannot be surgically removed) and metastatic melanoma (tumors that have spread to other organs) harboring the BRAF V6 Chemicalbook00E mutation, but not for the treatment of wild-type BRAF melanoma. Mekinist is used to treat BRAF V600E or V600...

Adagrasib is a highly specific and potent oral KRAS G12C inhibitor, optimized for durable target inhibition. This characteristic may be important for treating cancers with KRAS G12C mutations, as the KRAS G12C protein regenerates every 24-48 hours. Adagrasib has a long 24-hour half-life and broad tissue distribution, and it can cross the blood-brain barrier, helping to maximize drug efficacy. Adagrasib is approved by the FDA for the treatment of previously treated non-small cell lung cancer (NSCLC) and colorectal cancer harboring KRAS G12C mutations...